Search in:

Modern Rheumatology Volume 29, 2019 - Issue 3

Journal homepage

513

Views

CrossRef citations to date

Altmetric

Original Article

Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients

Koichiro IshikawaIshikawa Orthopaedic and Rheumatism Clinic, Kumamoto, JapanCorrespondence[email protected]

Junichiro IshikawaIshikawa Orthopaedic and Rheumatism Clinic, Kumamoto, Japan

Pages 418-429 | Received 29 Jun 2017, Accepted 22 May 2018, Published online: 23 Jul 2018

Cite this article
https://doi.org/10.1080/14397595.2018.1481565
CrossMark

Full Article
Figures & data
References
Supplemental
Citations
Metrics
Reprints & Permissions

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Haojun Shi, Shufeng Li, Yun Geng, Huancai Fan, Ruojia Zhang, Yuang Zhang, Jihong Pan, Guanhua Song, Luna Ge, Tianhua Xie & Lin Wang. (2022) Euphorbia factor L3 ameliorates rheumatoid arthritis by suppressing the inflammatory response by targeting Rac family small GTPase 1. Bioengineered 13:4, pages 10985-10998.
Read now

Saviana Gandolfo & Salvatore De Vita. (2019) Emerging drugs for primary Sjögren’s syndrome. Expert Opinion on Emerging Drugs 24:2, pages 121-132.
Read now

Articles from other publishers (13)

Dan Ouyang, Yuan Zhi Ma, Jie Zou, Yong Long Wang, Zheng Chen, Yu Ying Yang, Bin Zou, Xin Li & Jian Zhong Cao. (2022) Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology 13.
Crossref

Liuting Zeng, Qi He, Kailin Yang, Wensa Hao, Ganpeng Yu & Hua Chen. (2022) A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren’s Syndrome. Frontiers in Immunology 13.
Crossref

Zhou Hang, Jintao Wei, Ming Zheng, Zeping Gui, Hao Chen, Li Sun, Shuang Fei, Zhijian Han, Jun Tao, Zijie Wang, Ruoyun Tan & Min Gu. (2022) Iguratimod Attenuates Macrophage Polarization and Antibody-Mediated Rejection After Renal Transplant by Regulating KLF4. Frontiers in Pharmacology 13.
Crossref

Shu Kiyotoki, Jun Nishikawa, Jutaro Miyamoto, Koji Tanigawa, Seiji Tsuchida, Ryo Kawasato, Takao Nakashima, Takakazu Furutani, Hirokazu Ozawa, Mitsuru Yasunaga & Isao Sakaida. (2021) Delay of endoscopic submucosal dissection-induced gastric ulcer healing by methotrexate. Clinical Journal of Gastroenterology 14:3, pages 754-758.
Crossref

L.-J. Chen, Y.-J. Zhou, Z.-H. Wen, F. Tian & J.-Y. Li. (2020) Efficacy and safety of iguratimod combined with methotrexate vs. methotrexate alone in rheumatoid arthritisWirksamkeit und Sicherheit von Iguratimod in Kombination mit Methotrexat vs. Methotrexat allein bei rheumatoider Arthritis. Zeitschrift für Rheumatologie 80:5, pages 432-446.
Crossref

Rong Mu, Chun Li, Xiaomei Li, Yao Ke, Ling Zhao, Lin Chen, Rui Wu, Zhenbiao Wu, Xiaoxia Zuo, Yanli Xie, Jinwei Chen, Wei Wei, Yi Liu, Zhijun Li, Lie Dai, Lingyun Sun, Xiangyuan Liu & Zhanguo Li. (2021) Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study. The Lancet Regional Health - Western Pacific 10, pages 100128.
Crossref

Chang-hong Li, Zhen-zhen Ma, Lei-lei Jian, Xin-yu Wang, Lin Sun, Xiang-yuan Liu, Zhong-qiang Yao & Jin-xia Zhao. (2021) Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways. International Immunopharmacology 90, pages 107219.
Crossref

Nithya Murugesh, Ramasamy Karvembu & Seenuvasan Vedachalam. (2020) A Convenient Synthesis of Iguratimod‐Amine Precursor via NHC‐Catalyzed Aldehyde‐Nitrile Cross Coupling Reaction. ChemistrySelect 5:44, pages 13916-13918.
Crossref

Asuka Inoue, Yuji Nozaki, Yasuaki Hirooka, Koji Kinoshita, Yasutaka Chiba, Masanori Funauchi & Itaru Matsumura. (2020) The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care. Life 10:11, pages 261.
Crossref

Sisi Xie, Shu Li, Jing Tian & Fen Li. (2020) Iguratimod as a New Drug for Rheumatoid Arthritis: Current Landscape. Frontiers in Pharmacology 11.
Crossref

Huihui Jiang, Hongyan Gao, Qin Wang, Miao Wang & Bin Wu. (2020) Molecular mechanisms and clinical application of Iguratimod: A review. Biomedicine & Pharmacotherapy 122, pages 109704.
Crossref

Yanying Liu, Yuxin Zhang, Wenjie Bian, Jiangnan Fu, Xing Sun, Da Chen, Jiali Chen, Xiaozhen Zhao, Yingni Li, Wen Zhang & Zhanguo Li. (2019) Efficacy and safety of iguratimod on patients with relapsed or refractory IgG4-related disease. Clinical Rheumatology 39:2, pages 491-497.
Crossref

. (2019) Iguratimod/warfarin. Reactions Weekly 1758:1, pages 196-196.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients

Articles from other publishers (13)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years’ treatment for Japanese rheumatoid arthritis patients

Citations (15)

Read on this site (2)

Articles from other publishers (13)

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date